CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Buprenorphine/naloxone

Last Updated: March 6, 2008
Result type: Reports
Project Number: S0128
Product Line: Reimbursement Review

Generic Name: Buprenorphine/naloxone

Brand Name: Suboxone

Manufacturer: Schering-Plough Canada Inc

Indications: Opioid drug dependence (Substitution treatment)

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: September 24, 2008

Recommendation Type: List with clinical criteria and/or conditions